SIRNAX

siRNAx, Inc. is an early stage drug discovery and development company. The mission of siRNAx, Inc... siRNAx, Inc.'s initial disease target of Waldenstrom's macroglobulinemia. This disease is caused by the uncontrolled production of the IgM antibody. siRNAx, Inc.'s fusion protein will deliver the siRNA to the plasma cells which secrete the IgM. The siRNA will then turn off the production of the IgM in the malignant plasma cells.

Also known as: siRNAx, Inc.

Primary location: Ann Arbor United States